Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform
20 Luglio 2023 - 2:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Sartorius BIA
Separations, which is part of the international life science group
Sartorius, today shared new data that demonstrates the ability to
improve the recovery of full AAV capsids during anion-exchange
(AEX) purification, which will help gene therapy companies
streamline the downstream processing workflow. Teknova is a leading
producer of critical reagents for the discovery, development, and
commercialization of novel therapies, vaccines, and molecular
diagnostics, and Sartorius BIA Separations is a leading developer
of monolith-based technologies for the separation and analysis of
large biomolecules and viral particles.
Teknova presented the findings from the companies’ first
collaboration earlier this week during a presentation entitled,
“Enhancing AAV Full Capsid Enrichment with an Optimized AEX
Platform: A Case Study." After identifying capsid enrichment as a
critical pain point in the AAV gene therapy workflow, Teknova and
Sartorius BIA Separations began working together to address the
challenges gene therapy developers face. By using a robust design
of experiments (DOE) approach, the companies were able to achieve
more than 85 percent full capsid enrichment with 80-95 percent
recoveries using custom Teknova buffers along with the Sartorius
BIA Separations CIMmultus® QA monolith for the polishing step,
given a specific starting material of AAV8 that contained 46
percent full capsids. The buffers and parameters discovered in this
study were then further optimized to create a first-of-its-kind
product available off-the-shelf for gene therapy developers:
Teknova’s AAV-Tek AEX Buffer Screening Kit for AAV8.
“The findings from our first DOE with Sartorius BIA Separations
indicate a real advantage for gene therapy development when
leveraging a combination of Teknova’s proprietary reagents and
BIA’s AAV monolith platform,” said Stephen Gunstream, Teknova’s
President and Chief Executive Officer. “We’re committed to finding
new tools to help our customers streamline the development of AAV
therapies and these results illustrate how we can help accelerate
the discovery of novel breakthroughs to improve the health of
patients.”
“Our collaboration with Teknova has demonstrated two essential
components for the successful separation of AAV empty and full
capsids during the downstream polishing step: the purification
platform and the buffer composition,” said Aleš Štrancar, Managing
Director at Sartorius BIA Separations. “By combining our strengths,
we’ve been able to consistently reproduce results that indicate the
use of Teknova’s high-quality, custom buffer formulations with our
CIMmultus QA monolith increases the yield and purity of full AAV
particles.”
Gene therapy companies focusing on AAV8 now have a reliable and
scalable option for the enhancement of AAV full capsid enrichment
during the downstream purification process that could help save
months in process development. Teknova and Sartorius BIA
Separations continue to develop data demonstrating improvements in
AAV purification, and plan to share additional findings in the
future.
To see the data from the companies’ recent DOE, watch the
webinar here.
Consumables used during the DOE are now available through each
company’s website:
For information about Teknova’s AAV-Tek AEX Buffer Screening Kit
or to purchase it online, visit teknova.com.
For information about Sartorius BIA Separations CIMmultus QA
monoliths or to purchase one online, visit sartorius.com.
ABOUT
TEKNOVA Teknova makes
solutions possible. Since 1996, Teknova has been innovating the
manufacture of critical reagents for the life sciences industry to
accelerate the discovery and development of novel therapies that
will help people live longer, healthier lives. We offer fully
customizable solutions for every stage of the workflow, supporting
industry leaders in cell and gene therapy, molecular diagnostics,
and synthetic biology. Our fast turnaround of high-quality agar
plates, microbial culture media, buffers and reagents, and water
helps our customers scale seamlessly from RUO to GMP. Headquartered
in Hollister, California, with over 200,000 square feet of
state-of-the-art facilities, Teknova’s modular manufacturing
platform was designed by our team of scientists, engineers, and
quality control experts to efficiently produce the foundational
ingredients for the discovery and commercialization of novel
therapies.
ABOUT SARTORIUS BIA SEPARATIONSSartorius BIA
Separations develops and manufactures market-leading CIM®
monolithic chromatographic columns for the purification and
analysis of large biomolecules, such as viruses, plasmids, and
mRNA, which are applied in cell and gene therapies. The company’s
Cornerstone® Biomanufacturing Development Services are the result
of more than 20 years of hands-on experience with the most
challenging biopharmaceutical products and offer a comprehensive
approach of integrated process development solutions and novel
technology designed to improve the robustness and yield of large
biomolecules production while improving the safety of therapeutic
products. Sartorius BIA's technology for manufacturing-scale
purification is already used in the production of the first
commercialized advanced therapeutics; the company also has a keen
presence with novel drug candidates in the clinical pipeline.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Lug 2023 a Lug 2024